Intrasense (ALINS) - Net Assets
Based on the latest financial reports, Intrasense (ALINS) has net assets worth €-6.46 Million EUR (≈ $-7.55 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€7.99 Million ≈ $9.35 Million USD) and total liabilities (€14.45 Million ≈ $16.89 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Intrasense (ALINS) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-6.46 Million |
| % of Total Assets | -80.78% |
| Annual Growth Rate | N/A |
| 5-Year Change | -229.48% |
| 10-Year Change | -385.94% |
| Growth Volatility | 1022.59 |
Intrasense - Net Assets Trend (2008–2025)
This chart illustrates how Intrasense's net assets have evolved over time, based on quarterly financial data. Also explore how large is Intrasense's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Intrasense (2008–2025)
The table below shows the annual net assets of Intrasense from 2008 to 2025. For live valuation and market cap data, see how much is Intrasense worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €-6.46 Million ≈ $-7.55 Million |
-490.40% |
| 2024-12-31 | €1.65 Million ≈ $1.93 Million |
-77.31% |
| 2023-12-31 | €7.29 Million ≈ $8.52 Million |
+262.28% |
| 2022-12-31 | €2.01 Million ≈ $2.35 Million |
-59.66% |
| 2021-12-31 | €4.99 Million ≈ $5.83 Million |
+131.52% |
| 2020-12-31 | €2.15 Million ≈ $2.52 Million |
+275.92% |
| 2019-12-31 | €573.00K ≈ $669.90K |
-73.61% |
| 2018-12-31 | €2.17 Million ≈ $2.54 Million |
+62.37% |
| 2017-12-31 | €1.34 Million ≈ $1.56 Million |
-40.78% |
| 2016-12-31 | €2.26 Million ≈ $2.64 Million |
+1.43% |
| 2015-12-31 | €2.23 Million ≈ $2.60 Million |
-28.89% |
| 2014-12-31 | €3.13 Million ≈ $3.66 Million |
-12.83% |
| 2013-12-31 | €3.59 Million ≈ $4.20 Million |
-33.44% |
| 2012-12-31 | €5.40 Million ≈ $6.31 Million |
+4277.22% |
| 2011-12-31 | €123.29K ≈ $144.14K |
-92.86% |
| 2010-12-31 | €1.73 Million ≈ $2.02 Million |
-61.19% |
| 2009-12-31 | €4.45 Million ≈ $5.20 Million |
-9.24% |
| 2008-12-31 | €4.90 Million ≈ $5.73 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Intrasense's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1080910700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €2.64 Million | % |
| Other Components | €1.72 Million | % |
| Total Equity | €-6.46 Million | 100.00% |
Intrasense Competitors by Market Cap
The table below lists competitors of Intrasense ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Eastern Technical Engineering Public Company Limited
BK:ETE
|
$10.12 Million |
|
GlycoMimetics Inc
NASDAQ:GLYC
|
$10.13 Million |
|
Bodegas Riojanas S.A.
MC:RIO
|
$10.14 Million |
|
Logismos Information Systems S.A
AT:LOGISMOS
|
$10.14 Million |
|
SaveLend Group AB
ST:YIELD
|
$10.11 Million |
|
Ostin Technology Group Co Ltd
NASDAQ:OST
|
$10.11 Million |
|
Impedimed Ltd
AU:IPD
|
$10.10 Million |
|
The Global Smaller Companies Trust Plc
LSE:GSCT
|
$10.10 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Intrasense's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,654,000 to -6,457,160, a change of -8,111,160 (-490.4%).
- Net loss of 10,809,000 reduced equity.
- Other comprehensive income increased equity by 977,000.
- Other factors increased equity by 1,720,840.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-10.81 Million | -167.4% |
| Other Comprehensive Income | €977.00K | +15.13% |
| Other Changes | €1.72 Million | +26.65% |
| Total Change | €- | -490.40% |
Book Value vs Market Value Analysis
This analysis compares Intrasense's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | €0.78 | €0.23 | x |
| 2011-12-31 | €0.06 | €0.23 | x |
| 2012-12-31 | €1.70 | €0.23 | x |
| 2013-12-31 | €1.08 | €0.23 | x |
| 2014-12-31 | €0.74 | €0.23 | x |
| 2015-12-31 | €0.36 | €0.23 | x |
| 2016-12-31 | €0.22 | €0.23 | x |
| 2017-12-31 | €0.11 | €0.23 | x |
| 2018-12-31 | €0.11 | €0.23 | x |
| 2019-12-31 | €0.03 | €0.23 | x |
| 2020-12-31 | €0.09 | €0.23 | x |
| 2021-12-31 | €0.16 | €0.23 | x |
| 2022-12-31 | €0.06 | €0.23 | x |
| 2023-12-31 | €0.14 | €0.23 | x |
| 2024-12-31 | €0.03 | €0.23 | x |
| 2025-12-31 | €-0.12 | €0.23 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Intrasense utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -360.94%
- • Asset Turnover: 0.37x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-178.00%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | -92.52% | -156.11% | 0.20x | 2.90x | €-1.77 Million |
| 2011 | -1313.84% | -63.66% | 0.41x | 50.52x | €-1.63 Million |
| 2012 | -10.26% | -13.49% | 0.43x | 1.75x | €-1.09 Million |
| 2013 | -51.17% | -44.24% | 0.54x | 2.14x | €-2.20 Million |
| 2014 | -174.81% | -161.87% | 0.49x | 2.19x | €-5.79 Million |
| 2015 | -123.60% | -76.52% | 0.58x | 2.76x | €-2.97 Million |
| 2016 | -78.19% | -47.84% | 0.70x | 2.35x | €-1.99 Million |
| 2017 | -157.25% | -70.29% | 0.82x | 2.74x | €-2.24 Million |
| 2018 | -69.48% | -40.01% | 0.86x | 2.03x | €-1.73 Million |
| 2019 | -159.16% | -27.49% | 0.79x | 7.34x | €-969.30K |
| 2020 | -32.68% | -20.46% | 0.54x | 2.95x | €-919.40K |
| 2021 | -24.12% | -28.74% | 0.48x | 1.76x | €-1.70 Million |
| 2022 | -169.98% | -90.24% | 0.58x | 3.24x | €-3.62 Million |
| 2023 | -49.10% | -108.29% | 0.32x | 1.43x | €-4.31 Million |
| 2024 | -341.90% | -251.78% | 0.29x | 4.65x | €-5.82 Million |
| 2025 | 0.00% | -360.94% | 0.37x | 0.00x | €-10.16 Million |
Industry Comparison
This section compares Intrasense's net assets metrics with peer companies in the Health Information Services industry.
Industry Context
- Industry: Health Information Services
- Average net assets among peers: $31,403,630
- Average return on equity (ROE) among peers: -40.61%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Intrasense (ALINS) | €-6.46 Million | -92.52% | N/A | $10.11 Million |
| AbL Diagnostics SA (ABLD) | $7.37 Million | -0.34% | 0.02x | $42.45 Million |
| AMA Corp PLC (ALAMA) | $2.55 Million | -288.07% | 2.60x | $7.22 Million |
| SMAIO SA (ALSMA) | $-618.89K | 0.00% | 0.00x | $38.63 Million |
| Cegedim S.A. (CGM) | $111.29 Million | 14.41% | 1.68x | $145.99 Million |
| Equasens S. A. (EQS) | $66.92 Million | 20.20% | 0.52x | $549.40 Million |
| Media Lab SpA (MLLAB) | $902.63K | 10.13% | 0.67x | $8.48 Million |
About Intrasense
Intrasense S.A. designs and develops software solution for advanced visualization and analysis of multimodality medical images under the Myrian name worldwide. It offers the Myriad platform, a visualization solution that provides a suite of clinical tools and artificial intelligence algorithms for prostate, lung, and brain pathologies; and the Liflow solution, an oncological imaging platform that… Read more